
17 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251217473902/en/Circle-Pharma-Announces-Nomination-of-CID-165-an-Oral-First-in-class-Cyclin-D1-RxL-Inhibitor-as-Development-Candidate-for-its-Second-Oncology-Program

23 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251022605631/en/Circle-Pharma-Unveils-First-Preclinical-Data-from-Cyclin-D1-Program-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics

14 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251013978480/en/Circle-Pharma-Announces-Upcoming-Poster-Presentation-Highlighting-the-Anti-tumor-Potential-of-Cyclin-D1-RxL-Inhibition-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics